Great. Thank you. Well, it's great to be here today and get to share a little bit about the Arsenal story with you. U I'm Dr. Uma Chararma, a Princeton trained chemical engineer who's really passionate about creating new materials for medical devices. And I joined Arsenal originally as a research scientist um because of the big vision of the founders. So our founders have created um companies worth over a hundred billion dollars of value um really on the idea of part harnessing chemistry and material science in new ways and they looked at medical devices and said we need a company that's doing this in the medical device space and that's really where Arsenal was born. Uh and we've realized that vision today through three clinical stage products. Um our first product was actually a degradable uh stent for the chronic sinocitis space that was spun out into LRA therapeutics and we have two clinical stage products that sit within Arsenal today uh which are shown on this slide here. Uh rescue foam is an expandable foam uh and NeoCast is an injectable paste. And what I'll point out on this slide, I'm going to talk more about both of those products, but what I'll point out here is that these materials actually look quite different as you can see from the videos. And that's because what we're intending to treat with these two products are two very different conditions. And so the approach of the company has been to build the right material for each indication rather than sort of have one material that we try to um apply to a lot of different therapy areas. Our lead product is NeoCast which is a neurovvascular liquidolic and thank you John for prepping everybody for the neurovvascular uh the neurovvascular um space. Um I'll start by talking about uh three of the patients we treated in our clinical study, our recent clinical study. Um so Raymond had severe hand numbness. Um, Gail has a uh very uh difficult has a lot of difficulty walking because of her uh gate issues and Clifford has very severe debilitating headaches. All three of these patients suffer from a condition known as chronic subdural hematoma. Uh chronic subdural hematoma is essentially a bruise that forms on the surface of your brain. Uh typically this is in an elderly patient um and typically following some sort of trauma. uh which could be as little as hitting your head on the car door. Um this uh the patient is often anti-coagulated. So this bleed continues uh rather than healing becomes a persistent bleed forms a brain uh forms a bruise which becomes um leads to a mass effect that can actually cause very debilitating s uh symptoms like we saw on the previous Uh when I first started giving this presentation, most people were not uh aware of what chronic subdural hematoma was at all. Um but uh the projections show by 2030 the number of procedures that will be done for CSDH as it's known uh will surpass what is being done for stroke and so I think there's a lot more awareness now of this procedure uh and this is also because of investment um from the strategics uh large strategics have run um multi- u um multic-enter randomized global studies in this space with a lot of investment Um and what you'll see is these products were approved literally decades ago. Uh and thousands of patients have now been enrolled across the globe. The agents fit into two buckets. So there's a class of agents um that contain a cytotoxic solvent that's extremely painful for patients uh and another class that contain that are basically made of um superlue and that can be difficult to work with. So you know when you think about designing the ideal m uh material to put in your grandmother's brain you don't think let me start with the toxic solvent or let me start with superglue. Um but the the data on these studies has actually come out and has been very positive. So uh the data has shown that embleization is actually very safe uh and has a significant benefit and this data was published last fall in New England journal. Um it also shows that there's significant opportunities for a next generation agent where if you look at these studies 80% of the this elderly population um was put under a general anesthesia to do this minimally invasive procedure and it's again it's not because of the procedure but it's because of the pain of the agents Um the goal in this procedure is actually to get a material deep into the capillary beds where is the the at the source of the bleeding. So historically this has been treated surgically where you can remove the clot the the uh the bleeding relieve the symptoms but you haven't addressed the membranes that are leaking and that causes um recurrence and so the purpose of embleization is to get the material to the the deepest parts of the vessel. Uh what's actually been found is with the existing technologies because of the way they work they often aren't able to get that deep into the vessel structure. So we created NeoCast with the idea of addressing these concerns. Um and we started by creating something that was solvent-free and non-adhesive, but also we use sheer thinning science to create a material that would actually once it's in the blood struct the blood vessel flow to the deepest parts where you're actually trying to treat first and then back up to the catheter. So trying to actually address the problem rather than just sort of address the symptoms. And here you can see some of our pre-clinical data as compared to the market leading agent. Um and you can see on the uh this is all done in swine. You can see that our agent across the bottom we're able to get much deeper into the vessel structure and much more consistently. Um and we've actually quantified this and showed that we are able to get five times deeper into the vessel structure. So we translated these results into um human brains and we started in uh tumors uh because that's a pre-operative indication and so that was a lower regulatory regulatory burden using the same vessel that's used in chronic subdural hematoma. Uh we treated five patients there and what you can see is that we see excellent penetration into the tumor. So again translating what we saw in preclinical animals into human brains. And then that set the stage for us to do a first in human study in chronic subdural hematoma, our market of interest. Uh and we recently announced uh data on the first 15 patients on that study. Uh those patients were in two cohorts. In the first cohort, all the patients we treated uh as we started first with general anesthesia. Uh and those 10 patients have exited the study and being followed for six months. Uh and then we treated a cohort um of five patients all without general anesthesia. uh we showed that the product is very safe with no uh events related to Um and this just gives an example of one of the uh resolutions we see. This is a patient that did not have surgery and you can see they started with very large bilateral hematomas and by three months they were almost gone. Uh comparing again back to the market leader. So this is a study done from one of the koss at Stonybrook shown in black. You can see see with the with the existing agents the the size of the hematoma does get smaller. Our data shown in green u shows that uh we see a much faster recurrence uh resolution of those hematomas and with the market leader at uh six months they showed onethird of the hematomas had been resolved as opposed to with our data were showing an 89% resolution at that same time point. Uh we also treated five patients as I mentioned without general anesthesia. So either um uh under conscious sedation or completely awake and we demonstrated that the patient the procedure was completely pain-free um and the patients couldn't even tell when the injection had started. So that gives you an example of what we're trying to do with materials and um in as a device. Uh quickly I'll hit on our second product. Um so rescue foam the way I describe it is like a human fixat. So, if your tire goes flat, you use fix a flat to get to the gas station. Um, if in that same car accident, instead of your tire at your liver, and you're going to die before you reach a surgeon, the idea is that rescue foam can be injected and give you enough time to reach that surgeon alive. Um, I'm showing some of our early pre-clinical data here where um this is a mortality curve in swine uh showing survival as a function of time. And you can see without the product it's about a 6% survival rate at one hour versus with the product it's a 96% survival rate. So very marked difference. So I've um shown you sort of two examples of how we think about materials in and medical devices. Our two clinical stage uh programs here today. Uh, one of the things that's really cool about being in this space is every time we talk to a physician, they have more ideas about where different materials could be used across the body. Um, so I think there's a lot of tremendous potential here. Uh, all of this would not be uh possible without our amazing team and the the board um that support us and all the experience that they bring. Uh and we're currently at a point of inflection where we're um planning for the next phase uh the next clinical phase of NeoCast. So uh if you're interested in what I've talked about today, would love to chat more and um um share a little bit more details beyond the nine minutes of our journey. Thank you.